Viral hepatitis in practice

Viral hepatitis in practice - 2011

July 2011, Volume 3 Number 2

February 2011, Volume 3 Number 1

Tailoring response-based treatment for hepatitis C
Antonia Ho and Ray Fox
pp 1-5
The recommended treatment for chronic infection with hepatitis C virus (HCV) is a combination of pegylated interferon (pegIFN) alfa and ribavirin (RBV). Treatment duration is determined by HCV genotype: in genotype 1 (G1) infection, treatment usually lasts for 48 weeks, whereas in genotypes 2 and 3 (G2, G3), therapy for 24 weeks has been found to have equivalent efficacy.

Comment: A lesson from viral kinetics
Alastair Miller
pp 3-3
A few years ago, the treatment of chronic hepatitis C virus (HCV) infection seemed to be largely ‘sorted’. Although cure rates were suboptimal, treatment was mainly protocol-driven and managed in large, nurse-led interferon clinics. Patients with genotype 1 HCV received 48 weeks of pegylated interferon (pegIFN) and weightbased ribavirin (RBV), while those infected with genotype 2 or genotype 3 received 24 weeks of pegIFN and flat-dose RBV.

Identifying cases of chronic viral hepatitis: outreach in practice
Heather Lewis, Graham Foster and Katharine Burke
pp 6-7
Chronic viral hepatitis (CVH) caused by hepatitis B or C is a global health concern, with an estimated 350 million people worldwide chronically infected with the hepatitis B virus (HBV), and 170 million infected with the hepatitis C virus (HCV).

Modern management of HIV and hepatitis C virus co-infection
Alastair Miller
pp 8-10
The use of highly active antiretroviral therapy (HAART) for the treatment of HIV infection since 1996 has dramatically reduced AIDS-related morbidity and mortality. This has allowed chronic liver disease to emerge as a leading cause of death among HIV-infected patients; much of that liver disease relates to chronic coinfection with hepatitis viruses (either hepatitis B virus [HBV] or hepatitis C virus [HCV]).

Viral hepatitis in practice was previously supported by Gilead Sciences from 2015 to 2016, by Gilead Sciences and Janssen in 2014, by Gilead Sciences and Roche Products in 2013 and by Gilead Sciences from 2009 to 2012.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Viral hepatitis in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 2041-1162 (Print) ISSN 2045-7863 (Online)